Abstract
Background: Sclerostin is an osteocyte-derived circulating protein that inhibits the Wnt/β-catenin signaling pathway. The Wnt signaling pathway plays an important role in bone and dysregulation of the Wnt signaling pathway results in insulin resistance, inflammation, and metabolic disturbance. The aim of our study was to investigate the implication of sclerostin in low muscle mass in healthy subjects. Methods: The cross-sectional study analyzed 240 healthy non-diabetic subjects from the Korean Sarcopenic Obesity Study (KSOS). Low muscle mass was defined as the sum of the appendicular skeletal muscle mass divided by the square of height (ASM/height2) as proposed by the Asian Working Group for Sarcopenia. Results: Serum sclerostin was significantly higher in the low muscle mass group than the normal muscle mass group (151.3 [79.2-187.9] vs. 74.8 [47.6-119.6] pg/mL, p = 0.001). In the partial correlation analyses adjusted for age, sex, and body mass index, ASM/height2 was negatively associated with sclerostin levels (r = −0.245, p < 0.001). Furthermore, sclerostin levels decreased linearly according to the first, second, and third tertiles of ASM/height2 even after adjusting for sex, age, body mass index, life style parameters, fasting plasma glucose, bone mineral content (BMC), and total body fat mass. Conclusions: Serum sclerostin levels were negatively correlated to skeletal muscle mass independent of confounding factors including BMC and total body fat mass.
| Original language | English |
|---|---|
| Article number | 115053 |
| Journal | Bone |
| Volume | 128 |
| DOIs | |
| Publication status | Published - 2019 Nov 1 |
Fingerprint
Keywords
- Bone muscle interaction
- Low skeletal muscle mass
- Sclerostin
- Wnt pathway
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Physiology
- Histology
Cite this
Association of serum sclerostin levels with low skeletal muscle mass : The Korean Sarcopenic Obesity Study (KSOS). / Kim, Jung A.; Roh, Eun; Hong, So hyeon; Lee, You Bin; Kim, Nam Hoon; Yoo, Hye-Jin; Seo, Ji A.; Kim, Nan Hee; Kim, Sin Gon; Baik, Sei-Hyun; Choi, Kyung Mook.
In: Bone, Vol. 128, 115053, 01.11.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Association of serum sclerostin levels with low skeletal muscle mass
T2 - The Korean Sarcopenic Obesity Study (KSOS)
AU - Kim, Jung A.
AU - Roh, Eun
AU - Hong, So hyeon
AU - Lee, You Bin
AU - Kim, Nam Hoon
AU - Yoo, Hye-Jin
AU - Seo, Ji A.
AU - Kim, Nan Hee
AU - Kim, Sin Gon
AU - Baik, Sei-Hyun
AU - Choi, Kyung Mook
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Background: Sclerostin is an osteocyte-derived circulating protein that inhibits the Wnt/β-catenin signaling pathway. The Wnt signaling pathway plays an important role in bone and dysregulation of the Wnt signaling pathway results in insulin resistance, inflammation, and metabolic disturbance. The aim of our study was to investigate the implication of sclerostin in low muscle mass in healthy subjects. Methods: The cross-sectional study analyzed 240 healthy non-diabetic subjects from the Korean Sarcopenic Obesity Study (KSOS). Low muscle mass was defined as the sum of the appendicular skeletal muscle mass divided by the square of height (ASM/height2) as proposed by the Asian Working Group for Sarcopenia. Results: Serum sclerostin was significantly higher in the low muscle mass group than the normal muscle mass group (151.3 [79.2-187.9] vs. 74.8 [47.6-119.6] pg/mL, p = 0.001). In the partial correlation analyses adjusted for age, sex, and body mass index, ASM/height2 was negatively associated with sclerostin levels (r = −0.245, p < 0.001). Furthermore, sclerostin levels decreased linearly according to the first, second, and third tertiles of ASM/height2 even after adjusting for sex, age, body mass index, life style parameters, fasting plasma glucose, bone mineral content (BMC), and total body fat mass. Conclusions: Serum sclerostin levels were negatively correlated to skeletal muscle mass independent of confounding factors including BMC and total body fat mass.
AB - Background: Sclerostin is an osteocyte-derived circulating protein that inhibits the Wnt/β-catenin signaling pathway. The Wnt signaling pathway plays an important role in bone and dysregulation of the Wnt signaling pathway results in insulin resistance, inflammation, and metabolic disturbance. The aim of our study was to investigate the implication of sclerostin in low muscle mass in healthy subjects. Methods: The cross-sectional study analyzed 240 healthy non-diabetic subjects from the Korean Sarcopenic Obesity Study (KSOS). Low muscle mass was defined as the sum of the appendicular skeletal muscle mass divided by the square of height (ASM/height2) as proposed by the Asian Working Group for Sarcopenia. Results: Serum sclerostin was significantly higher in the low muscle mass group than the normal muscle mass group (151.3 [79.2-187.9] vs. 74.8 [47.6-119.6] pg/mL, p = 0.001). In the partial correlation analyses adjusted for age, sex, and body mass index, ASM/height2 was negatively associated with sclerostin levels (r = −0.245, p < 0.001). Furthermore, sclerostin levels decreased linearly according to the first, second, and third tertiles of ASM/height2 even after adjusting for sex, age, body mass index, life style parameters, fasting plasma glucose, bone mineral content (BMC), and total body fat mass. Conclusions: Serum sclerostin levels were negatively correlated to skeletal muscle mass independent of confounding factors including BMC and total body fat mass.
KW - Bone muscle interaction
KW - Low skeletal muscle mass
KW - Sclerostin
KW - Wnt pathway
UR - http://www.scopus.com/inward/record.url?scp=85071532579&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071532579&partnerID=8YFLogxK
U2 - 10.1016/j.bone.2019.115053
DO - 10.1016/j.bone.2019.115053
M3 - Article
AN - SCOPUS:85071532579
VL - 128
JO - Bone
JF - Bone
SN - 8756-3282
M1 - 115053
ER -